Strengthening the influenza vaccine virus selection and development process. Outcome of the 2nd WHO Informal Consultation for Improving Influenza Vaccine Virus Selection held at the Centre International de Conférences (CICG) Geneva, Switzerland, 7 to 9 December 2011

Vaccine

Volumn 31, Issue 32, 2013, Pages 3209-3221

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

INFLUENZA VACCINE;

ANTIBODY RESPONSE; ANTIGENICITY; CONFERENCE PAPER; DISEASE SURVEILLANCE; DRUG MARKETING; INFLUENZA; INFLUENZA VIRUS; INFLUENZA VIRUS A H1N1; INFLUENZA VIRUS A H3N2; PRIORITY JOURNAL;

ANTIBODY FORMATION; ANTIGENS, VIRAL; CONGRESSES AS TOPIC; DRUG INDUSTRY; EPIDEMIOLOGICAL MONITORING; HEMAGGLUTINATION INHIBITION TESTS; HUMANS; IMMUNIZATION PROGRAMS; INFLUENZA VACCINES; INFLUENZA, HUMAN; INTERNATIONAL COOPERATION; NEUTRALIZATION TESTS; ORTHOMYXOVIRIDAE; SWITZERLAND; WORLD HEALTH ORGANIZATION;

EID: 84879460234     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2013.05.049     Document Type: Conference Paper

References (31)

1. Legrand J., Vergu E., Flahault A. Real-time monitoring of the influenza vaccine field effectiveness. Vaccine 2006, 24(44-46):6605-6611.
2. Improving influenza vaccine virus selection. Report of a WHO informal consultation. WHO headquarters, Geneva, Switzerland, 14-16 June 2010. Influenza Other Respir Viruses 2012, 6:142-152. WHO Writing Group.
3. Herfst S., Schrauwen E.J., Linster M., Chutinimitkul S., de Wit E., Munster V.J., et al. Airborne transmission of influenza A/H5N1 virus between ferrets. Science 2012, 336(6088):1534-1541.
4. Imai M., Watanabe T., Hatta M., Das S.C., Ozawa M., Shinya K., et al. Experimental adaptation of an influenza H5 HA confers respiratory droplet transmission to a reassortant H5 HA/H1N1 virus in ferrets. Nature 2012, 486(7403):420-428.
5. Continued evolution of highly pathogenic avian influenza A (H5N1): updated nomenclature. Influenza Other Respir Viruses 2012, 6(1):1-5. WHO/OIE/FAO H5N1 Evolution Working Group.
6. Lindstrom S., Garten R., Balish A., Shu B., Emery S., Berman L., et al. Human infections with novel reassortant influenza A(H3N2)v viruses, United States, 2011. Emerg Infect Dis 2012, 18(5):834-837.
7. Lin Y.P., Gregory V., Collins P., Kloess J., Wharton S., Cattle N., et al. Neuraminidase receptor binding variants of human influenza A(H3N2) viruses resulting from substitution of aspartic acid 151 in the catalytic site: a role in virus attachment?. J Virol 2010, 84(13):6769-6781.
8. Stephenson I., Heath A., Major D., Newman R.W., Hoschler K., Junzi W., et al. Reproducibility of serologic assays for influenza virus A (H5N1). Emerg Infect Dis 2009, 15(8):1252-1259.
9. Cate T.R., Rayford Y., Niño D., Winokur P., Brady R., Belshe R., et al. A high dosage influenza vaccine induced significantly more neuraminidase antibody than standard vaccine among elderly subjects. Vaccine 2010, 28:2076-2079.
10. Sandbulte M.R., Westgeest K.B., Gao J., Xu X., Klimov A.I., Russell C.A., et al. Discordant antigenic drift of neuraminidase and hemagglutinin in H1N1 and H3N2 influenza viruses. Proc Natl Acad Sci 2011, 108(51):20748-20753.
11. Smith D.R., Lapedes A.S., de Jong J.C., Bestebroer T.M., Rimmelzwaan G.F., Osterhaus A.D.M.E., et al. Mapping the antigenic and genetic evolution of influenza virus. Science 2004, 305(5682):371-376.
12. Khurana S., Suguitan A.L., Rivera Y., Simmons C.P., Lanzavecchia A., Sallusto F., et al. Antigenic fingerprinting of H5N1 avian influenza using convalescent sera and monoclonal antibodies reveals potential vaccine and diagnostic targets. PLoS Med 2009, 6(4):e1000049.
13. Khurana S., Verma N., Talaat K.R., Karron R.A., Golding H. Immune response following H1N1pdm09 vaccination: differences in antibody repertoire and avidity in young adults and elderly populations stratified by age and gender. J Infect Dis 2012, 205:610-620.
14. Moody M.A., Zhang R., Walter E.B., Woods C.W., Ginsburg G.S., McClain M.T., et al. H3N2 influenza infection elicits more cross-reactive less clonally expanded anti-hemagglutinin antibodies than influenza vaccination. PLoS ONE 2011, 6(10):e25797.
15. Khurana S., Verma N., Yewdell J.W., Hilbert A.K., Castellino F., Lattanzi M., et al. MF59 adjuvant enhances diversity and affinity of antibody-mediated immune response to pandemic influenza vaccines. Sci Transl Med 2011, 3(85):85ra48.
16. Hardy S., Eichelberger M., Griffiths E., Weir J.P., Wood D., Alfonso C. Confronting the next pandemic - workshop on lessons learned from potency testing of pandemic (H1N1) 2009 influenza vaccines and considerations for future potency tests, Ottawa, Canada, July 27-29 2010. Influenza Other Respir Viruses 2011, 5:438-442.
17. Khurana S., Larkin C., Verma S., Joshi M.B., Fontana J., Steven A.C., et al. Recombinant HA1 produced in E. coli forms functional oligomers and generates strain-specific SRID potency antibodies for pandemic influenza vaccines. Vaccine 2011, 29(34):5657-5665.
18. Abelin A., Colegate T., Gardner S., Hehme N., Palache A. Lessons from pandemic influenza A(H1N1): the research-based vaccine industry's perspective. Vaccine 2011, 29(6):1135-1138.
19. Jadhav S.S., Gautam M., Gairola S. Emerging markets & emerging needs: developing countries vaccine manufacturers' perspective & its current status. Biologicals 2009, 37(3):165-168.
20. Friede M., Palkonyay L., Alfonso C., Pervikov Y., Torelli G., Wood D., et al. WHO initiative to increase global and equitable access to influenza vaccine in the event of a pandemic: supporting developing country production capacity through technology transfer. Vaccine 2011, 29(Suppl. 1):A2-A7.
21. Kawaoka Y. Unpublished.
22. Klimov A.I., Garten R., Russell C., Barr I.G., Besselaar T.G., Daniels R., et al. WHO recommendations for the viruses to be used in the 2012 Southern Hemisphere Influenza Vaccine: epidemiology, antigenic and genetic characteristics of influenza A(H1N1)pdm09, A(H3N2) and B influenza viruses collected from February to September 2011. Vaccine 2012, 30(45):6461-6471.
23. Greninger A.L., Chen E.C., Sittler T., Scheinerman A., Roubinian N., Yu G., et al. A metagenomic analysis of pandemic influenza A (2009 H1N1) infection in patients from North America. PLoS ONE 2010, 5(10):e13381.
24. Shapira S.D., Gat-Viks I., Shum B.O.V., Dricot A., de Grace M.M., Wu L., et al. A physical and regulatory map of host-influenza interactions reveals pathways in H1N1 infection. Cell 2009, 139(7):1255-1267.
25. Ghedin E., Fitch A., Boyne A., Griesemer S., Depasse J., Bera J., et al. Mixed infection and the genesis of influenza virus diversity. J Virol 2009, 83(17):8832-8841.
26. Ghedin E., Laplante J., Depasse J., Wentworth D.E., Santos R.P., Lepow M.L., et al. Deep sequencing reveals mixed infection with 2009 pandemic influenza A (H1N1) virus strains and the emergence of oseltamivir resistance. J Infect Dis 2011, 203(2):168-174.
27. Cao Y., Koh X., Dong L., Du X., Wu A., Ding X., et al. Rapid estimation of binding activity of influenza virus hemagglutinin to human and avian receptors. PLoS ONE 2011, 6(4):e18664.
28. Du X., Dong L., Lan Y., Peng Y., Wu A., Zhang Y., et al. Mapping of H3N2 influenza antigenic evolution in China reveals a strategy for vaccine strain recommendation. Nat Commun 2011, 3:709.
29. Bahl J., Nelson M.I., Chan K.H., Chen R., Vijaykrishna D., Halpin R.A., et al. Temporally structured metapopulation dynamics and persistence of influenza A H3N2 virus in humans. Proc Natl Acad Sci U S A 2011, 108:19359-19364.
30. Chan J., Holmes A., Rabadan R. Network analysis of global influenza spread. PLoS Comput Biol 2010, 6(11):e1001005.
31. Russell C.A., Jones T.C., Barr I.G., Cox N.J., Garten R.J., Gregory V., et al. The global circulation of seasonal influenza A (H3N2) viruses. Science 2008, 320(5874):340-346.